Infants Born With Type 1 Spinal Muscular Atrophy May Have Increased Expression Of Functional SMN Protein After Risdiplam Therapy, Research Indicates

Neurology Advisor (3/31, Nye) reports, “Infants born with type 1 spinal muscular atrophy had increased expression of functional survival of motor neuron (SMN) protein after risdiplam therapy,” investigators concluded in a two-part, “phase 2-3, open label...